Background PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming
to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy …

Background Malaria in pregnancy has major impacts on mother and child health. To
complement existing interventions, such as intermittent preventive treatment and use of …

In areas where Plasmodium falciparum transmission is endemic, clinical immunity against
malaria is progressively acquired during childhood and adults are usually protected against …

Over the past 10 years, knowledge of the burden, economic costs, and consequences of
malaria in pregnancy has improved, and the prevalence of malaria caused by Plasmodium …

Placental malaria (PM) due to Plasmodium falciparum is a major cause of maternal, fetal
and infant mortality, but the mechanisms of pathogenesis and protective immunity are …

Placental malaria is caused by Plasmodium falciparum–infected erythrocytes that bind to
placental tissue. Binding is mediated by VAR2CSA, a parasite antigen coded by the var …

Background Pregnancy-associated malaria (PAM) is precipitated by the accumulation of
parasites in the placental intervillous spaces and causes maternal anemia and low birth …

Background. How antimalarial antibodies are acquired and maintained during pregnancy
and boosted after reinfection with Plasmodium falciparum and Plasmodium vivax is …

Background In endemic areas, pregnant women are highly susceptible to Plasmodium
falciparum malaria characterized by the accumulation of parasitized red blood cells (pRBC) …

VAR2CSA mediates sequestration of Plasmodium falciparum-infected erythrocytes in the
placenta, increasing the risk of poor pregnancy outcomes. Naturally acquired antibodies …